The evolution of strategies to minimise the risk of human drug-induced liver injury (DILI) in drug discovery and development
PA Walker, S Ryder, A Lavado, C Dilworth… - Archives of toxicology, 2020 - Springer
Early identification of toxicity associated with new chemical entities (NCEs) is critical in
preventing late-stage drug development attrition. Liver injury remains a leading cause of …
preventing late-stage drug development attrition. Liver injury remains a leading cause of …
Predicting transporter mediated drug–drug interactions via static and dynamic physiologically based pharmacokinetic modeling: A comprehensive insight on where …
G Vijaywargi, S Kollipara, T Ahmed… - … & Drug Disposition, 2023 - Wiley Online Library
The greater utilization and acceptance of physiologically‐based pharmacokinetic (PBPK)
modeling to evaluate the potential metabolic drug–drug interactions is evident by the …
modeling to evaluate the potential metabolic drug–drug interactions is evident by the …
Research landscape of physiologically based pharmacokinetic model utilization in different fields: a bibliometric analysis (1999–2023)
X Wang, J Wu, H Ye, X Zhao, S Zhu - Pharmaceutical Research, 2024 - Springer
Purpose The physiologically based pharmacokinetic (PBPK) modeling has received
increasing attention owing to its excellent predictive abilities. However, there has been no …
increasing attention owing to its excellent predictive abilities. However, there has been no …
Mechanistic in vitro studies indicate that the clinical drug–drug interactions between protease inhibitors and rosuvastatin are driven by inhibition of intestinal BCRP …
R Elsby, H Coghlan, J Edgerton… - Pharmacology …, 2023 - Wiley Online Library
Previous use of a mechanistic static model to accurately quantify the increased rosuvastatin
exposure due to drug–drug interaction (DDI) with coadministered atazanavir underpredicted …
exposure due to drug–drug interaction (DDI) with coadministered atazanavir underpredicted …
Studying the right transporter at the right time: an in vitro strategy for assessing drug-drug interaction risk during drug discovery and development
R Elsby, H Atkinson, P Butler… - Expert Opinion on Drug …, 2022 - Taylor & Francis
Introduction Transporters are significant in dictating drug pharmacokinetics, thus inhibition of
transporter function can alter drug concentrations resulting in drug-drug interactions (DDIs) …
transporter function can alter drug concentrations resulting in drug-drug interactions (DDIs) …
Contribution of humanized liver chimeric mice to the study of human hepatic drug transporters: state of the art and perspectives
A Zerdoug, M Le Vée, S Uehara, B Lopez… - European journal of …, 2022 - Springer
Chimeric mice with humanized livers constitute an attractive emergent experimental model
for investigating human metabolism and disposition of drugs. The present review was …
for investigating human metabolism and disposition of drugs. The present review was …
Mechanistic in vitro studies indicate that the clinical drug-drug interaction between telithromycin and simvastatin acid is driven by time-dependent inhibition of CYP3A4 …
R Elsby, V Hare, H Neal, S Outteridge, C Pearson… - Drug Metabolism and …, 2019 - ASPET
A previous attempt to accurately quantify the increased simvastatin acid exposure due to
drug-drug interaction (DDI) with coadministered telithromycin, using a mechanistic static …
drug-drug interaction (DDI) with coadministered telithromycin, using a mechanistic static …
UPLC–MS/MS method for the simultaneous quantification of pravastatin, fexofenadine, rosuvastatin, and methotrexate in a hepatic uptake model and its application to …
W Wu, R Cheng, Z Jiang, L Zhang… - Biomedical …, 2021 - Wiley Online Library
A rapid and specific UPLC–MS/MS method with a total run time of 3.5 min was developed for
the determination of pravastatin, fexofenadine, rosuvastatin, and methotrexate in rat primary …
the determination of pravastatin, fexofenadine, rosuvastatin, and methotrexate in rat primary …
Identification and quantitation of enzyme and transporter contributions to hepatic clearance for the assessment of potential drug-drug interactions
E Kimoto, RS Obach, MVS Varma - Drug Metabolism and …, 2020 - Elsevier
Drug-drug interactions (DDIs) involving drug-metabolizing enzymes and membrane
transporters can lead to alteration in substrate drug (victim) exposure, and can influence the …
transporters can lead to alteration in substrate drug (victim) exposure, and can influence the …
他克莫司转运蛋白基因多态性在器官移植中的研究进展.
张函舒， 宋沧桑， 张阳， 李兴德 - Organ Transplantation/Qi …, 2021 - search.ebscohost.com
他克莫司(Tac) 是器官移植术后常用的免疫抑制剂, 具有良好的免疫抑制效果, 但Tac
的药代动力学存在较大个体差异, 其中基因多态性是主要的影响因素. 近年来 …
的药代动力学存在较大个体差异, 其中基因多态性是主要的影响因素. 近年来 …